Engineered NK cells kill NY-ESO-1 peptide–HLA-A*02:01–positive tumor cells via TCR-mediated recognition and perforin/granzyme release. IL-15 signals through CD132 on the NK cells to enhance their function; cells expressing CD132 are not targeted for killing.